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Background: Due to the high rate of asymptomatic infections an advanced screening assay is of prompt importance
to be used for the clinical diagnosis of HCV. Early detection of anti HCV is the first step in the management of chronic
hepatitis and in the selection of patients needing treatments. In the current study we have first time used the
advanced serological diagnostic technique i.e. Chemiluminescent Microparticle Immuno Assay (CMIA) for the
detection of HCV infection in Peshawar Pakistan.
Methods: A total number of 982 samples were collected among the general public belongs to the different areas
of district Peshawar. The samples were centrifuged at high speed to obtain a clear supernatant serum. All the
samples were run on Architect system a fully automated immuno analyzer CMIA base technology.
Results: Out of 982 blood samples analyzed in this study, 160 (15.9%) were confirmed to be positive for active
HCV infection. The overall prevalence was found to be 13.4%. Gender wise prevalence was recorded to be higher
in male (19.1%) than female (12.7%). The age group 21-30 years was identified as the highest risk group among
the studied population.
Conclusion: Among the tested samples, overall prevalence of active HCV infection was found to be 13.4% in the
general population of Peshawar Pakistan. The young middle aged population of this region was at higher risk of
HCV ailments compared to the other age groups.
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Hepatitis C is a viral infectious disease of liver. At early
stages the infection is asymptomatic but once established,
it can progress to advanced liver diseases such as liver
fibrosis and ultimately cirrhosis. These liver diseases can
further lead to other complications such as liver failure
and liver cancer [1]. HCV is a plus-stranded RNA virus
and is a distinct member of the familyFlaviviridae. HCV
has infected about 200 million people worldwide which
are about 3.3% of the world population [2]. Approximately
20-30% of patients naturally clear the virus. About 70-80%
acute HCV infections become chronic that leads to the
development of cirrhosis in 20% of cases while the same* Correspondence: adenzai_ia@yahoo.com
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article, unless otherwise stated.percentage of patients becomes victim of hepatocellular
carcinoma. Acute hepatitis C occurs during the first six
months of HCV infection [3].
Prevalence of HCV varies throughout the world. Liver
cirrhosis is a major cause of mortality and HCV related
liver cancer is the 8th common cancer worldwide [4,5].
In Pakistan, more than 10 million people are suffering
from HCV that comprise 6% of total population, with
high morbidity and mortality [6]. In previous studies
high HCV prevalence was reported in other cities of
Pakistan. There were 16% in Lahore, 20.6% in Faisalabad
and 23.8% in Gujranwala [7] but no such report is there
as far as Peshawar region is concerned.
Due to high rate of asymptomatic infections, an advanced
screening assay is of prompt importance to be used for the
clinical diagnosis of HCV. Early anti HCV detection is the
first step in the management of chronic hepatitis in ordertral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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methods are implemented for the diagnosis of hepatitis
infection i.e. Immune Chromatographic Technique (ICT),
Enzyme Linked Immuno Sorrbant Assay (ELISA) and
HCV-RNA by PCR, but due to the false positivity rate of
HCV with ICT based methods, ELISA is considered to be
more consistent than ICT based HCV diagnosis [9]. The
detection of HCV RNA by PCR is more reliable; however,
PCR assay is costly, has technical hitches and it needs
skilled personnel for the operation and interpretation of
the output. Patients in this region with low socioeconomic
status will not be able to afford it. The current study we
have focused on, the Chemiluminescent Microparticle
Immuno Assay (CMIA), an advanced serological diagnos-
tic technique, provides a rapid, cost-effective and reliable
way to detect HCV, and therefore, is the method that was
implemented for the diagnosis of hepatitis infection.
Results and discussion
A total of 982 blood samples were collected from the
district Peshawar Pakistan and were screened for anti
HCV. The current study was carried out during February,
2013-14. Among 982 samples 127 were detected as HCV
positive. Figure 1 shows a prevalence of HCV positive
samples in different age groups with respect to male/
female population. As shown in Table 1, the gender-wise
prevalence of active HCV infection was estimated to be
15.4% in male (84 positive out of 543 samples) and 9.7%
in female subjects (43 positive out of 439 samples) re-
spectively. Considering the age group criterion, significant
differences were observed in the prevalence of HCV in
both genders. The highest prevalence of 18.5% was ob-
served in age group 21-30 (p = 0.9407, OR = 0.972, 95%
CI = 0.470-2.014), however statistically significant active
HCV infection was noted in age group 31-40 with a
prevalence of 17.2% (p = 0.0007, OR = 4.626, 95% CI =
1.802-11.88). Both of these values are higher compared
to the age group 11–20 years having a prevalence of 3.7%Figure 1 Prevalence of HCV positive samples in different age groups(p = 0.5889, OR = 0.607, 95% CI = 0.098-3.761). The age
groups of 41-50 and > 50 was associated with a decrease
trend of active HCV prevalence of 13.1% (p = 0.1757,
OR = 1.803, 95% CI = 0.761-4.268) and 14.6% (p = 0.2740,
OR = 1.595, 95% CI = 0.687-3.701) respectively.
Previous reports on HCV prevalence in other regions
of Khyber Pakhtunkhwa, Pakistan were shown in Table 2.
A high prevalence of HCV (57% and 36%) was observed
among the thalassaemic patients [10,11]. Others regions
like Mardan, Risalpur, Peshawar, Abbottabad and Bunner
showed HCV prevalence as 3.69%, 3.40%, 2.20%, 8% and
4.57% respectively.
Hepatitis C virus (HCV) is a major cause of liver disease
and has a high potential to cause significant morbidity and
mortality worldwide [17]. Prevalence of HCV in Pakistan
is the highest in the world and estimated to be 4.8% [18].
Currently, about 10 million people are infected with HCV
in Pakistan [19]. The prevalence of hepatitis C varies in
different provinces of Pakistan. It was found to be high in
Sind and Punjab that is 5-6% [20]. The present study was
conducted during February, 2013-14 in order to find
out the prevalence of HCV among the general public of
district Peshawar, Pakistan.
We have found the overall prevalence of HCV as 13.4%
which is higher than 4.9% previously reported among the
general public of Lahore, Pakistan [1]. This major differ-
ence among the overall prevalence may be due to using of
different diagnostic techniques in the laboratories, im-
munological status of the persons and lack of awareness
regarding hepatitis C virus particularly in district Peshawar
Pakistan. Another study conducted among the healthy
donors in Bolichistan Pakistan reported 20.8% prevalence
which was slightly higher than our present study [21].
This is due to the lack of education, poverty and un-
hygienic health status of the people in the region.
In the current study the incidence of HCV was higher in
the age group 21-30 years i.e. 18.5% which is in accordance
with the previously reported results [21]. High prevalencewith respect to male/female population.
Table 1 Frequency of HCV positive samples among different age groups and overall prevalence
Age groups (years) Sample size Male +/- Female +/- p value Odds ratio Confidence interval Overall prevalence (%)
01-10 80 00/50 00/30 - - - -
11-20 135 02/68 03/62 0.5889 0.607 0.098-3.761 3.7
21-30 200 22/98 15/65 0.9407 0.972 0.470-2.014 18.5
31-40 185 26/74 06/79 0.0007*** 4.626 1.802-11.88 17.2
41-50 198 17/88 09/84 0.1757 1.803 0.761-4.268 13.1
> 50 184 17/81 10/76 0.2740 1.595 0.687-3.701 14.6
Total 982 84/459 43/396 - - - 13.4
Chi-square test was applied and p < 0.05 was considered as significant at 95% confidence interval.
***p = value is significant.
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21-25 years pregnant women in Sindh [22], which were
higher than our present study, but the overall prevalence of
hepatitis C virus was found to be as higher in the middle
age group of the population in both studies.
The most terrible condition which we have observed
in this study is the high prevalence of HCV in the young
and middle aged people i.e. 21-30 and 31-40 years old
respectively. A number of studies conducted on the preva-
lence of Hepatitis C virus in different areas of Pakistan
[1,21] showed high incidence of Hepatitis C virus pre-
vailed in these age groups. The occurrence of hepatitis
among these age groups are contributed by lack of aware-
ness, used of unsterile syringes, repeated use of razors and
contaminated scissors for different customers without
prior sterilization. It was observed that about 90% of bar-
bers did not washed hands, 80% did not changed aprons
and 66% did not changed towels after each customer [23].
Another bad practice which made the environments
worse is the recycling of used syringes. A very young
scavenger of waste products around 18 to 20 years of
age sells 20-25 syringes per day to the health care waste
dealers against money and the same child gets needle
stick injury around none to three times per week [24].
The occurrence of hepatitis C virus found in the age
group >50 years was 14.6% in the current study which is
in accordance with the previously reported data [25].Table 2 HCV prevalence in other regions of Khyber
Pakhtunkhwa Pakistan
Region Method Population size HCV prevalence Reference
Mardan ELISA 15550 3.69% [12]
Risalpur ELISA 2558 3.40% [13]
Peshawar MEIA 3430 2.20% [14]
Abbotabad ELISA 102 8% [15]
Bunner ELISA 16400 4.57% [16]
Peshawar ELISA 80 36% [11]
NWFP(KPK) ELISA 250 57% [10]The overall prevalence of active HCV among different
aged groups reported in KPK, Pakistan was 7% by using
ICT techniques [26] was much lower than our present
study (13.4%). This disagreement is due to small sample
size in the former study and unreliable serological diag-
nostic techniques (ICT) used having low specificity and
sensitivity.
The frequent methods used for the diagnosis of HCV
infection based on the detection of anti HCV antibodies
in the serum or plasma, but nevertheless the concentration
of these antibodies reaches to detectable level after a long
window period of HCV infection. Additionally viruses
eliminating from the blood but still their presence in
the serum or plasma for a long period of time could not
differentiate between current and past HCV infection.
At the same time methods used like ELISA and CMIA
for detection of anti HCV antibodies gives false positive
results. These false positive results for anti HCV are
likely in population having low HCV prevalence due to
some cross reactivity of others viral antigen and antibodies
in individual have immune disorder [27-29]. According to
the CDC all the screening methods used for the detection
of anti HCV need supplementary methods like HCV
RNA or nucleic acid testing (NAT) for their further
confirmation. In the current study the detection of anti
HCV antibodies by CMIA techniques have some disad-
vantages of giving false positive results, therefore further
tests like NAT to detect HCV RNA is needed. However in
spite of these recommendations supplementary tests are
not performed in many laboratories due to some reasons
which include technical complexity of the methods, high
cost, long procedures. In such condition the guidelines set
issued by CDC recommendations including option to use
a signal to cutoff ratios to limit the number of the samples
needing supplemental testing. According to CDC guide-
lines [30] the FDA approved anti HCV screening kits
(ELISA, CMIA and RIBA) establishes specific signals to
cutoff ratio which is S/CO ≥5.0 for chemiluminescent
immunoassay by architect system from Abbott diagnos-
tic services which predicted a true antibodies positive
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results for the tested samples were obtained where
serum index (S/CO ≥5.0).
In the present study anti HCV detection was done by
using a very sensitive and more advance diagnostic tech-
nique CMIA on the stat of the art Architect system
which is a fully automated immuno analyzer of Abbott
diagnostic services.
Conclusions
In this study we have used the most reliable, sensitive
and advanced serological diagnostic technique for the
detection of HCV antibodies in serum of infected per-
sons. Among the tested samples, overall prevalence of
active HCV infection was found to be 13.4% in the gen-
eral population of Peshawar Pakistan. The HCV infec-
tion prevailed among all age groups but young middle
age population of this region was at higher risk of HCV
ailments compared to the other age groups. This study
will be helpful to the health care policy makers to design
strategies for controlling and eradication of Hepatitis C
infection in Peshawar, Pakistan.
Methods
Sample collection
A total number of 982 sample were collected among the
general public belongs to different areas of district
Peshawar Pakistan. About 3 cc blood is collected from
each individual in gel vaccutainer tube. The relevant dem-
ography of the persons was recorded in separate forms.
The age groups included in this study was 01-80 years.
Sample processing
The samples were centrifuged at high speed about
8000 rpm for 15 minutes in order to obtain a clear
supernatant serum. All the samples were run on Archi-
tect system which is fully automated immuno analyzer
of the Abbott diagnostic services.
Chemiluminescent Microparticle Immuno Assay (CMIA)
Chemiluminescent Microparticle Immuno Assay is the
modified and advanced form of the Enzyme Linked
Immuno Sorrbant Assay (ELISA) technique. Architect
system is designed to detect antibodies to putative struc-
tural and non structural protein (HCr-43, c-100, NS3,
NS4) of HCV genome [31]. In the final reaction of Anti
HCV detection, bound achridinylated conjugates were
used to generate chemiluminescent signals. Results were
obtained automatically by the software by comparing the
chemiluminescent signals obtained from the reaction
product of the sample with the signal of the cutoff value
previously obtained by Anti HCV calibration. The overall
specificity and sensitivity of this method is 99.6% and
99.7% respectively.Statistical analysis
Data was analyzed statistically by using GraphPad Prism
5 (GraphPad Software Inc. San Diego CA, USA). The
Chi-square test was used to analyze the qualitative data. A
p value < 0.05 was considered as significant. Odds ratio
with 95% confidence interval was used to evaluate the as-
sociation of various age groups with respect to HCV status
of male/female population.
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